Save up to 65% on Rafinlar - made in Europe - same as Tafinlar - available for immediate shipment.
Rafinlar comes in English packaging.
Information about Rafinlar (Dabrafenib)
Rafinlar is a prescription medication that contains dabrafenib as its active ingredient. It belongs to a class of drugs known as BRAF inhibitors. Dabrafenib works by targeting and inhibiting mutated BRAF proteins that drive the growth of certain cancers, especially those with a BRAF mutation. It is used to treat certain types of cancer, particularly melanoma and non-small cell lung cancer, where the BRAF gene mutation is present.
Product Highlights
- Rafinlar is approved for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, either alone or in combination with trametinib (a MEK inhibitor).
- For patients with non-small cell lung cancer harboring a BRAF V600E mutation, dabrafenib is used to help control tumor growth.
- Dabrafenib may also be used in combination with trametinib for anaplastic thyroid cancer (ATC) with BRAF mutations.
- It is under investigation for use in other cancers with BRAF mutations, including certain types of colorectal cancer.
Key Ingredient
Key Benefits
- Dabrafenib specifically targets cancer cells with the BRAF mutation, reducing damage to healthy tissues.
- Demonstrated significant efficacy in treating advanced melanoma, particularly those with BRAF V600 mutations.
- In some studies, dabrafenib, particularly when used in combination with trametinib, has shown improved progression-free survival in patients with BRAF-mutant cancers.
- Works well in combination with other targeted treatments (e.g., trametinib) to enhance effectiveness.
Direction of Use
- Oral capsules.
- The usual dose is 150 mg twice daily, but this can vary based on the specific indication and patient's response. It should be taken at the same time every day, with or without food.
- Patients on Rafinlar should be monitored for side effects, including skin reactions, fever, and liver function abnormalities.
- Often prescribed in combination with trametinib (a MEK inhibitor) for better efficacy in cancers like melanoma.
Safety Concerns
- Common side effects
- Skin rash or new skin cancer (cutaneous squamous cell carcinoma)
- Fever and chills (pyrexia)
- Headache
- Fatigue
- Nausea and vomiting
- Joint pain
Serious side effects
- Risk of serious heart problems such as QT prolongation.
- Liver enzyme elevations, which could indicate liver injury.
- Vision changes, including retinal vein occlusion.
- Risk of blood clots, especially when combined with trametinib.
- Increased risk of secondary cancers, particularly skin cancers.
Interactions
- May interact with other drugs that affect liver enzymes or those that affect the heart's rhythm.
- Should be used with caution in patients taking other medications that affect the immune system, blood thinners, or chemotherapy agents.
Avoid Rafinlar (Dabrafenib) If
- Patients who are allergic to dabrafenib or any of its components should avoid using Rafinlar.
- Should be avoided in pregnant women as it may cause harm to the fetus.
- Not recommended during breastfeeding as dabrafenib can pass into breast milk.
- Patients with severe liver conditions should avoid using Rafinlar.
- Those with a history of QT interval prolongation or other significant heart problems should not take Rafinlar without careful monitoring.
